To include your compound in the COVID-19 Resource Center, submit it here.

Galapagos falls on CF data, AbbVie partnership update

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) shares slid Friday after the company said GLPG2737 failed to significantly improve lung function in the Phase II PELICAN trial to treat cystic fibrosis. The company also said partner AbbVie Inc. (NYSE:ABBV) has scrapped plans for

Read the full 405 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE